Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - JPMorgan initiated coverage on Avalon Technologies Ltd (NSE:AVALON) with an Underweight rating and a price target of INR650.00 on Wednesday.
The investment bank cited two structural issues behind its negative outlook on the electronic manufacturing services company. JPMorgan expressed concern about Avalon’s high export exposure, which accounts for 57% of the company’s revenues and faces uncertainty due to the current tariff environment.
The firm also noted that Avalon’s lower domestic exposure (43% of revenues) is problematic because the domestic market offers greater opportunities. JPMorgan believes Avalon needs to scale up its domestic business to match competitors’ growth rates.
JPMorgan’s earnings per share estimates for fiscal years 2026-2028 are 15-25% below consensus, primarily due to lower margin expectations for the company.
The bank values Avalon at 36 times June 2027 earnings, below peers Syrma (39x) and Kaynes (62x), a discount JPMorgan considers justified due to lower growth expectations for Avalon Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.